Comparison of 60 or 90 mg/m2of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics-Reference-Cited by-同舟云学术

Comparison of 60 or 90 mg/m2of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics

Published:2014-11-19 Issue:2 Volume:90 Page:E29-E30
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Devillier Raynier¹²,Bertoli Sarah³,Prébet Thomas¹,Huguet Françoise³,Etienne Anne¹,Charbonnier Aude¹,Rey Jérôme¹,Delabesse Eric³⁴,D'Incan Evelyne¹,Huynh Anne³,Blaise Didier¹⁴,Récher Christian³⁴,Vey Norbert¹²

Affiliation:

1. Hematology Department; Institut Paoli Calmettes; Marseille France

2. Aix-Marseille University; Medecine Faculty; Marseille France

3. Département D'hématologie; Institut Universitaire du Cancer Toulouse - Oncopole; Toulouse France

4. Toulouse University; Medecine Faculty; Toulouse France

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.23884/fullpdf

Reference13 articles.

1. High-dose daunorubicin in older patients with acute myeloid leukemia;Löwenberg;N Engl J Med,2009

2. Anthracycline dose intensification in acute myeloid leukemia;Fernandez;N Engl J Med,2009

3. Long-term results of a randomized phase 3 trial comparing idarubicin and daunorubicin in younger patients with acute myeloid leukaemia;Récher;Leukemia,2014

4. Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: Long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study group;Bertoli;Haematologica,2014

5. Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia;Prebet;Haematologica,2014

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase II study of cladribine, idarubicin, and ara‐C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia;American Journal of Hematology;2023-08-27

2. Paradigm Shift in the Management of Acute Myeloid Leukemia—Approved Options in 2023;Cancers;2023-05-31

3. Venetoclax combined with daunorubicin and cytarabine (2 + 6) as induction treatment in adults with newly diagnosed acute myeloid leukemia: a phase 2, multicenter, single-arm trial;Experimental Hematology & Oncology;2023-05-12

4. Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial;The Lancet Haematology;2022-06

5. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial;The Lancet Haematology;2021-08